Global Post Herpetic Neuralgia Patches Market Size By Type (Lidocaine Skin Patches, Capsaicin Skin Patches), By Application (Hospital Pharmacies, Online Pharmacies), By Region, And Segment Forecasts,...

The Global Post Herpetic Neuralgia (PHN) Patches Market was valued at USD 1.3 billion in 2023 and is projected to reach USD 2.6 billion by 2031, growing at a CAGR of 9.2% during the forecast period (2023–2031). The market is witnessing robust growth due to increasing prevalence of herpes zoster infections, rising geriatric population susceptible to nerve-related complications, and growing awareness about non-invasive pain management therapies. PHN patches, particularly those utilizing lidocaine or capsaicin, have emerged as effective treatments for managing chronic neuropathic pain without systemic side effects, driving their global adoption.

Drivers:

1. Rising Incidence of Herpes Zoster:

The increasing number of herpes zoster cases globally, especially among the elderly, is a primary growth driver. PHN is a common complication of shingles, necessitating long-term pain management solutions such as transdermal patches.

2. Preference for Non-Invasive Therapies:

Patients and clinicians increasingly prefer non-invasive treatment options that offer localized relief, fewer side effects, and greater convenience, boosting the uptake of PHN patches.

3. Expansion of Geriatric Population:

As aging is a major risk factor for PHN, the growth of the elderly demographic worldwide is directly fueling demand for effective post-herpetic pain relief solutions.

Restraints:

1. Limited Efficacy in Severe Cases:

While PHN patches provide symptomatic relief, they may offer limited efficacy in severe or widespread cases, leading to dependence on adjunct therapies.

2. Regulatory and Reimbursement Challenges:

Variations in reimbursement policies and regulatory hurdles, especially in developing countries, may impede market penetration and product accessibility.

Opportunity:

1. Innovation in Patch Technology:

Advances in drug delivery systems, such as microneedle patches and sustained-release formulations, offer opportunities for enhanced efficacy and patient compliance.

2. Growing Awareness in Emerging Markets:

Educational campaigns and improved healthcare access in emerging economies are creating untapped opportunities for market players to expand their presence.

3. Strategic Collaborations and Product Launches:

Pharmaceutical companies are engaging in partnerships and product innovations to strengthen portfolios and leverage global distribution channels.

Market by System Type Insights:

Based on system type, lidocaine patches dominated the market in 2023 due to their proven safety profile and effectiveness in reducing localized nerve pain. These patches are often the first-line treatment in PHN and are widely prescribed in clinical settings. Capsaicin patches, though less commonly used due to initial discomfort, are gaining traction due to their long-lasting effects and reduced dosing frequency.

Market by End-use Insights:

The hospital pharmacies segment held the largest market share in 2023, driven by high prescription rates and the availability of specialized pain management programs. However, retail pharmacies are expected to witness the fastest growth due to the increasing shift towards outpatient treatment and over-the-counter availability of certain PHN patches.

Market by Regional Insights:

North America led the global PHN patches market in 2023, supported by high disease awareness, established healthcare infrastructure, and the presence of key market players. Meanwhile, Asia-Pacific is projected to grow at the fastest pace during the forecast period due to rising healthcare expenditure, aging population, and increasing incidence of shingles in countries like Japan, China, and South Korea.

Competitive Scenario:

Key players in the Global PHN Patches Market include Endo Pharmaceuticals, Teva Pharmaceuticals, Acorda Therapeutics, Grünenthal GmbH, Hisamitsu Pharmaceutical Co., Inc., Mylan N.V., Scilex Pharmaceuticals, Inc., and Pfizer Inc. These companies are actively involved in launching next-generation transdermal products, expanding their global footprint, and securing regulatory approvals. Notable developments include:

2023: Hisamitsu launched a high-strength lidocaine patch in Japan targeting PHN with improved adhesive properties.

2024: Scilex Pharmaceuticals initiated a Phase III trial for a novel capsaicin patch targeting multi-day efficacy.

2025: Grünenthal expanded its partnership in Latin America to commercialize Qutenza, its capsaicin-based patch.

Scope of Work – Global Post Herpetic Neuralgia Patches Market

Report Metric Details

Market Size (2023) USD 1.3 billion

Projected Market Size (2031) USD 2.6 billion

CAGR (2023–2031) 9.2%

Market Segments System Type (Lidocaine, Capsaicin), End-Use (Hospital Pharmacies, Retail Pharmacies)

Growth Drivers Rising Herpes Zoster Cases, Preference for Non-Invasive Treatments, Aging Population

Opportunities Patch Innovation, Awareness in Emerging Markets, Strategic Collaborations